COVID-19 and Drug Repurposing

COVID-19 has expedited research on drug repurposing, a method that entails repurposing current pharmaceuticals. This strategy has proven invaluable throughout the pandemic since it makes use of well-known medications to promptly meet urgent requirements. Drugs that were initially designed for other illnesses, such as remdesivir and dexamethasone, have been proven to have therapeutic benefits for COVID-19 patients. Repurposing medications can lead to treatment more quickly than creating new ones from scratch. It also makes use of pre-existing safety data, which is important for responding to quickly changing health emergencies.

  • Mechanisms of Drug Repurposing
  • Clinical Trials and Evidence
  • Drug Candidates for COVID-19

  • Mechanisms of drug repurposing
  • Drug candidates for COVID-19

Related Conference of COVID-19 and Drug Repurposing

February 24-25, 2025

2nd International Conference on Pharmacognosy

Madrid, Spain
February 27-28, 2025

8th International on Pharmacy and Pharmaceutical Conference

Prague, Czech Republic
March 10-11, 2025

35th Annual European Pharma Congress

Rome, Italy
April 14-15, 2025

18th European Biosimilars Congress

Paris, France
April 24-25, 2025

18th World Drug Delivery Summit

London, UK
May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Aix-en-Provence, France
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland

COVID-19 and Drug Repurposing Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in